CA2890459A1 - Ultra low density pulmonary powders - Google Patents
Ultra low density pulmonary powders Download PDFInfo
- Publication number
- CA2890459A1 CA2890459A1 CA2890459A CA2890459A CA2890459A1 CA 2890459 A1 CA2890459 A1 CA 2890459A1 CA 2890459 A CA2890459 A CA 2890459A CA 2890459 A CA2890459 A CA 2890459A CA 2890459 A1 CA2890459 A1 CA 2890459A1
- Authority
- CA
- Canada
- Prior art keywords
- particles
- pharmaceutical composition
- powder
- tap density
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
- A61J3/071—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use into the form of telescopically engaged two-piece capsules
- A61J3/074—Filling capsules; Related operations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B1/00—Packaging fluent solid material, e.g. powders, granular or loose fibrous material, loose masses of small articles, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
- B65B1/04—Methods of, or means for, filling the material into the containers or receptacles
- B65B1/16—Methods of, or means for, filling the material into the containers or receptacles by pneumatic means, e.g. by suction
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B1/00—Packaging fluent solid material, e.g. powders, granular or loose fibrous material, loose masses of small articles, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
- B65B1/20—Reducing volume of filled material
- B65B1/26—Reducing volume of filled material by pneumatic means, e.g. suction
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B1/00—Packaging fluent solid material, e.g. powders, granular or loose fibrous material, loose masses of small articles, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
- B65B1/30—Devices or methods for controlling or determining the quantity or quality or the material fed or filled
- B65B1/36—Devices or methods for controlling or determining the quantity or quality or the material fed or filled by volumetric devices or methods
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B63/00—Auxiliary devices, not otherwise provided for, for operating on articles or materials to be packaged
- B65B63/02—Auxiliary devices, not otherwise provided for, for operating on articles or materials to be packaged for compressing or compacting articles or materials prior to wrapping or insertion in containers or receptacles
- B65B63/028—Auxiliary devices, not otherwise provided for, for operating on articles or materials to be packaged for compressing or compacting articles or materials prior to wrapping or insertion in containers or receptacles by pneumatic means
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mechanical Engineering (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Psychology (AREA)
- Quality & Reliability (AREA)
- Dispersion Chemistry (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Basic Packing Technique (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Oil, Petroleum & Natural Gas (AREA)
Abstract
The invention provides pharmaceutical compositions for pulmonary delivery comprising particles containing a pharmaceutical agent and having a geometric size of greater than about 5 µm and a tap density of less than about 0.075 g/cm3. The invention also provides methods for delivering the pharmaceutical compositions of the invention to the respiratory tract of a patient.
Description
ULTRA LOW DENSITY PULMONARY POWDERS
RELATED APPLICATIONS
This application claims the benefit of U.S. Provisional Application No.
61/724,781, filed on November 9, 2012; U.S. Provisional Application No.
61/884,319;
U.S. Provisional Application No. 61/884,315; U.S. Provisional Application No.
61/884,436, all filed on September 30, 2013. This application is a continuation-in-part of Application No. 13/679,245, filed November 16, 2012, now U.S. Patent 8,545,878 and a continuation-in-part of U.S. Application No. 13/945,160, filed July 18, 2013.
The entire teachings of the above applications are incorporated herein by reference.
BACKGROUND OF THE INVENTION
Delivering large doses of drug through the pulmonary route is very difficult.
Dry powder inhalers offer advantages in delivering high dose drugs. In a dry powder formulation, choosing a formulation with a high percentage of drug and a low percentage of excipient can help delivery high dose drugs, but it can often be difficult to manufacture and use such powders. Applicants have discovered an ultralow density pulmonary dry powder which allows for high doses of the powder to be packaged in a delivery compartment while being released from the inhaler as highly respirable particles.
SUMMARY OF THE INVENTION
The invention provides pharmaceutical compositions for pulmonary delivery comprising particles containing a pharmaceutical agent and having a geometric size of greater than about 5iiim and a tap density of less than about 0.075 g/cm3. The invention also provides methods for delivering the pharmaceutical compositions of the invention to the respiratory tract of a patient. In one embodiment, the pharmaceutical compositions include particles comprising levodopa for pulmonary delivery to the respiratory tract of a patient suffering from Parkinson's disease.
DETAILED DESCRIPTION OF THE INVENTION
In one embodiment, the invention is a pharmaceutical composition for pulmonary delivery comprising particles containing a pharmaceutical agent and having a median geometric size of greater than about 5 microns (lam) and a tap density of less than about 0.075 g/cm3. In one aspect of the invention, the tap density is from about 0.02 to 0.075 g/cm3. In another aspect of the invention, the tap density is from about 0.02 to 0.05 g/cm3. In a further aspect of the invention, the tap density is from about 0.03 to 0.06 g/cm3. In one aspect of the invention, the tap density is from about 0.03 to 0.04 g/cm3.
In another aspect of the invention the median geometric size is about 5p.m to 30p.m, 5p.m to 10p.m, 7p.m to 15 p.m, or 7p.m to 12p.m.
In another embodiment, the invention is a method of delivering a pharmaceutical agent to the pulmonary system of a patient comprising the steps of:
providing a powder in a compartment and an inhaler to a patient wherein said powder comprises particles of a pharmaceutical agent;
dispersing the powder by breath actuation of the patient;
delivering the particles to the patient's respiratory system;
wherein upon dispersion of the powder, the particles delivered to the patient's respiratory system have a smaller median geometric diameter than the particles contained in said compartment.
In one aspect of the invention, the powder has a tap density of less than about 0.75 g/cm3, from about 0.02 to 0.075 g/cm3, or from about 0.025 to 0.055 g/cm3.
In one aspect of this invention, an inhaler is a dry powder inhaler. A variety of inhalers can be used including the Aerolizer, Diskus, Flexhaler, Handihaler, Neohaler, Pressair, Rotahaler, Turbohaler, and Twisthaler. Other dry powder inhalers which can be used are described in US patent 6,766,799, US patent 7,278,425 and US patent 8,496,002 each of which are hereby incorporated in by reference for their disclosure relating to the inhalation devices described therein.
In one aspect of the invention, the compartment is a capsule or a blister pack. In one aspect of the invention, the inhaler has a resistance of about 0.05 to about 0.25, about 0.15 to about 0.25, 0.05 to about 0.15, 0.2 to about 0.25, or about 0.2.
Resistance as referred herein is measured in: square root of cm H20/(Liters/minute).
In another aspect of the invention, the powder in said compartment has a median geometric diameter of greater than about 5 p.m, of about 5 p.m to about 30 p.m, of about 5 p.m to about 15 p.m, or of about 7 p.m to about 12 p.m. In one specific embodiment, the
RELATED APPLICATIONS
This application claims the benefit of U.S. Provisional Application No.
61/724,781, filed on November 9, 2012; U.S. Provisional Application No.
61/884,319;
U.S. Provisional Application No. 61/884,315; U.S. Provisional Application No.
61/884,436, all filed on September 30, 2013. This application is a continuation-in-part of Application No. 13/679,245, filed November 16, 2012, now U.S. Patent 8,545,878 and a continuation-in-part of U.S. Application No. 13/945,160, filed July 18, 2013.
The entire teachings of the above applications are incorporated herein by reference.
BACKGROUND OF THE INVENTION
Delivering large doses of drug through the pulmonary route is very difficult.
Dry powder inhalers offer advantages in delivering high dose drugs. In a dry powder formulation, choosing a formulation with a high percentage of drug and a low percentage of excipient can help delivery high dose drugs, but it can often be difficult to manufacture and use such powders. Applicants have discovered an ultralow density pulmonary dry powder which allows for high doses of the powder to be packaged in a delivery compartment while being released from the inhaler as highly respirable particles.
SUMMARY OF THE INVENTION
The invention provides pharmaceutical compositions for pulmonary delivery comprising particles containing a pharmaceutical agent and having a geometric size of greater than about 5iiim and a tap density of less than about 0.075 g/cm3. The invention also provides methods for delivering the pharmaceutical compositions of the invention to the respiratory tract of a patient. In one embodiment, the pharmaceutical compositions include particles comprising levodopa for pulmonary delivery to the respiratory tract of a patient suffering from Parkinson's disease.
DETAILED DESCRIPTION OF THE INVENTION
In one embodiment, the invention is a pharmaceutical composition for pulmonary delivery comprising particles containing a pharmaceutical agent and having a median geometric size of greater than about 5 microns (lam) and a tap density of less than about 0.075 g/cm3. In one aspect of the invention, the tap density is from about 0.02 to 0.075 g/cm3. In another aspect of the invention, the tap density is from about 0.02 to 0.05 g/cm3. In a further aspect of the invention, the tap density is from about 0.03 to 0.06 g/cm3. In one aspect of the invention, the tap density is from about 0.03 to 0.04 g/cm3.
In another aspect of the invention the median geometric size is about 5p.m to 30p.m, 5p.m to 10p.m, 7p.m to 15 p.m, or 7p.m to 12p.m.
In another embodiment, the invention is a method of delivering a pharmaceutical agent to the pulmonary system of a patient comprising the steps of:
providing a powder in a compartment and an inhaler to a patient wherein said powder comprises particles of a pharmaceutical agent;
dispersing the powder by breath actuation of the patient;
delivering the particles to the patient's respiratory system;
wherein upon dispersion of the powder, the particles delivered to the patient's respiratory system have a smaller median geometric diameter than the particles contained in said compartment.
In one aspect of the invention, the powder has a tap density of less than about 0.75 g/cm3, from about 0.02 to 0.075 g/cm3, or from about 0.025 to 0.055 g/cm3.
In one aspect of this invention, an inhaler is a dry powder inhaler. A variety of inhalers can be used including the Aerolizer, Diskus, Flexhaler, Handihaler, Neohaler, Pressair, Rotahaler, Turbohaler, and Twisthaler. Other dry powder inhalers which can be used are described in US patent 6,766,799, US patent 7,278,425 and US patent 8,496,002 each of which are hereby incorporated in by reference for their disclosure relating to the inhalation devices described therein.
In one aspect of the invention, the compartment is a capsule or a blister pack. In one aspect of the invention, the inhaler has a resistance of about 0.05 to about 0.25, about 0.15 to about 0.25, 0.05 to about 0.15, 0.2 to about 0.25, or about 0.2.
Resistance as referred herein is measured in: square root of cm H20/(Liters/minute).
In another aspect of the invention, the powder in said compartment has a median geometric diameter of greater than about 5 p.m, of about 5 p.m to about 30 p.m, of about 5 p.m to about 15 p.m, or of about 7 p.m to about 12 p.m. In one specific embodiment, the
- 2 -particles in said compartment have a median geometric diameter of 10-12 nm and the particles delivered to the patient's respiratory tract have a median geometric diameter of 8-9 m. In another embodiment, the particles delivered to the patient's respiratory tract have a 5% to 20% smaller, 5% to 10% smaller, or 8% to 15% smaller median geometric diameter than the particles in said compartment.
In one embodiment, the invention is a pharmaceutical composition for pulmonary deliver comprising particles of levodopa having a geometric size of greater than about 5nm and a tap density of less than about 0.075 g/cm3. In one aspect of this invention, the particles comprise a phospholipid. In another aspect of this invention, the particles comprise a salt. In a further aspect of this invention, the particles comprise a surfactant or a polymer.
In one embodiment, particles of this invention have an external surface area of greater than 10m2/g. In another embodiment, the external surface area is greater than 15m2/g, greater than 20m2/g or about 10 m2/g to about 50 m2/g.
In one specific embodiment, the invention is a pharmaceutical composition for pulmonary deliver comprising particles of levodopa having a geometric size of about 8 nm to about 12 nm and a tap density of about 0.025 g/cm3 to about 0.050 g/cm3.
This specific invention, in some instances, may be characterized by particles having an aerodynamic diameter of between about 2.5nm and 5 nm, particles having an external surface area of about 10 m2/g to about 50 m2/g, or said particles further comprising a salt and a phospholipid. In one very specific embodiment, the invention is a pharmaceutical composition for pulmonary delivery comprising particles of levodopa, dipalmitoylphosphatidylcholine and sodium chloride, wherein said particles have a geometric size of about 8 nm to about 12 nm and a tap density of about 0.025 g/cm3 to about 0.050 g/cm3. In an even more specific embodiment, the invention is a pharmaceutical composition for pulmonary delivery comprising particles of levodopa, dipalmitoylphosphatidylcholine (DPPC) and sodium chloride, wherein said particles have a geometric size of about 8 nm to about 12 m, and a tap density of about 0.025 g/cm3 to about 0.050 g/cm3, an aerodynamic diameter of between about 2.5 nm and 5 nm, and an external surface area of about 10 to about 50 m2/g.
In one embodiment, the invention is a pharmaceutical composition for pulmonary deliver comprising particles of levodopa having a geometric size of greater than about 5nm and a tap density of less than about 0.075 g/cm3. In one aspect of this invention, the particles comprise a phospholipid. In another aspect of this invention, the particles comprise a salt. In a further aspect of this invention, the particles comprise a surfactant or a polymer.
In one embodiment, particles of this invention have an external surface area of greater than 10m2/g. In another embodiment, the external surface area is greater than 15m2/g, greater than 20m2/g or about 10 m2/g to about 50 m2/g.
In one specific embodiment, the invention is a pharmaceutical composition for pulmonary deliver comprising particles of levodopa having a geometric size of about 8 nm to about 12 nm and a tap density of about 0.025 g/cm3 to about 0.050 g/cm3.
This specific invention, in some instances, may be characterized by particles having an aerodynamic diameter of between about 2.5nm and 5 nm, particles having an external surface area of about 10 m2/g to about 50 m2/g, or said particles further comprising a salt and a phospholipid. In one very specific embodiment, the invention is a pharmaceutical composition for pulmonary delivery comprising particles of levodopa, dipalmitoylphosphatidylcholine and sodium chloride, wherein said particles have a geometric size of about 8 nm to about 12 nm and a tap density of about 0.025 g/cm3 to about 0.050 g/cm3. In an even more specific embodiment, the invention is a pharmaceutical composition for pulmonary delivery comprising particles of levodopa, dipalmitoylphosphatidylcholine (DPPC) and sodium chloride, wherein said particles have a geometric size of about 8 nm to about 12 m, and a tap density of about 0.025 g/cm3 to about 0.050 g/cm3, an aerodynamic diameter of between about 2.5 nm and 5 nm, and an external surface area of about 10 to about 50 m2/g.
- 3 -The inhalation powder may contain additional excipients. Examples of excipients include salts such as sodium chloride (NaC1), sodium citrate, sodium lactate, and potassium chloride and phospholipids such as dipalmitoylphosphatidylcholine (DPPC) dilatiroylphosphatidylcholine (DLPC), disatarated-phosphatidylcholine (DSPC). In one embodiment, the pharmaceutical composition contains a powder comprising 90% levodopa, 8% dipalmitoylphosphatidylcholine, and 2% sodium chloride as measured by % of dry solids in the powder. In one embodiment the pharmaceutical composition contains an inhalable powder having a dry weight ratio of 90:8:2 of levodopa:DPPC:NaCl. In another embodiment the capsule contains an inhalable powder having a dry weight ratio of 90:5:5 of levodopa:DPPC:NaCl.
Gravimetric analysis, using Cascade impactors, is a method of measuring the size distribution of airborne particles. The Andersen Cascade Impactor (ACT) is an eight-stage impactor that can separate aerosols into nine distinct fractions based on aerodynamic size. The size cutoffs of each stage are dependent upon the flow rate at which the ACT is operated. Preferably the ACT is calibrated at 60 L/min. In one embodiment, a two-stage collapsed ACT is used for particle optimization. The two-stage collapsed ACT consists of stages 0, 2 and F of the eight-stage ACT and allows for the collection of two separate powder fractions. At each stage an aerosol stream passes through the nozzles and impinges upon the surface. Particles in the aerosol stream with a large enough inertia will impact upon the plate. Smaller particles that do not have enough inertia to impact on the plate will remain in the aerosol stream and be carried to the next stage.
The ACT is calibrated so that the fraction of powder that is collected on a first stage is referred to herein as "fine particle fraction" or "FPF". The FPF
corresponds to the percentage of particles that have an aerodynamic diameter of less than 5.6 i.tm. The fraction of powder that passed the first stage of the ACT and is deposited on the collection filter is referred to as "FPF(3.4)". This corresponds to the percentage of particles having an aerodynamic diameter of less than 3.4 i.tm.
The FPF fraction has been demonstrated to correlate to the fraction of the powder that is deposited in the lungs of the patient, while the FPF(3.4) has been demonstrated to correlate to the fraction of the powder that reaches the deep lung of a patient. In
Gravimetric analysis, using Cascade impactors, is a method of measuring the size distribution of airborne particles. The Andersen Cascade Impactor (ACT) is an eight-stage impactor that can separate aerosols into nine distinct fractions based on aerodynamic size. The size cutoffs of each stage are dependent upon the flow rate at which the ACT is operated. Preferably the ACT is calibrated at 60 L/min. In one embodiment, a two-stage collapsed ACT is used for particle optimization. The two-stage collapsed ACT consists of stages 0, 2 and F of the eight-stage ACT and allows for the collection of two separate powder fractions. At each stage an aerosol stream passes through the nozzles and impinges upon the surface. Particles in the aerosol stream with a large enough inertia will impact upon the plate. Smaller particles that do not have enough inertia to impact on the plate will remain in the aerosol stream and be carried to the next stage.
The ACT is calibrated so that the fraction of powder that is collected on a first stage is referred to herein as "fine particle fraction" or "FPF". The FPF
corresponds to the percentage of particles that have an aerodynamic diameter of less than 5.6 i.tm. The fraction of powder that passed the first stage of the ACT and is deposited on the collection filter is referred to as "FPF(3.4)". This corresponds to the percentage of particles having an aerodynamic diameter of less than 3.4 i.tm.
The FPF fraction has been demonstrated to correlate to the fraction of the powder that is deposited in the lungs of the patient, while the FPF(3.4) has been demonstrated to correlate to the fraction of the powder that reaches the deep lung of a patient. In
- 4 -accordance with the invention, the FPF of the inhalable powder of the nominal dose contained in the capsule (i.e., the percentage of particles in the powder contained in the capsule that have an aerodynamic diameter of less than 5.6 p.m) is about 40%
or more.
In one embodiment the FPF of the nominal powder dose of the inhalable powder contained in the capsule is about 50%, 60%, or 70%, or 80%, or 90%. In one embodiment the FPF is about 50% to about 60% of the nominal powder dose of the inhalable powder contained in the inhaler. In one embodiment the FPF is about 55% to about 65% of the nominal powder dose of the inhalable powder contained in the inhaler.
In one embodiment the FPF is about 50% to about 70% of the nominal powder dose of the inhalable powder contained in the inhaler. In one embodiment the FPF is about 57%
to about 62% of the nominal powder dose of the inhalable powder contained in the inhaler. In one embodiment the FPF is about 50% to about 69% of the nominal powder dose of the inhalable powder contained in the inhaler. In one embodiment the FPF is about 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, or 65% of the nominal powder dose of the inhalable powder contained in the inhaler.
As used herein, the term "nominal powder dose" is the total amount of powder held in the capsule. As used herein, the term "nominal drug dose" is the total amount of drug (e.g. levodopa) contained in the nominal powder dose. The nominal powder dose is related to the nominal drug dose by the load percent of drug in the powder.
In one embodiment, the nominal powder dose is 25-50 mg by dry weight. In a further embodiment, the nominal powder dose is 25-40 mg by dry weight. In a still further embodiment, the nominal powder dose is 30-35 mg by dry weight or 32-38 mg by dry weight.
Another method for measuring the size distribution of airborne particles is the multi-stage liquid impinger (MSLI). The Multi-stage liquid Impinger (MSLI) operates on the same principles as the Anderson Cascade Impactor (ACT), but instead of eight stages there are five in the MSLI. Additionally, instead of each stage consisting of a solid plate, each MSLI stage consists of a methanol-wetted glass frit. The wetted stage is used to prevent bouncing and re-entrainment, which can occur using the ACT. The MSLI
is used to provide an indication of the flow rate dependence of the powder. This can be
or more.
In one embodiment the FPF of the nominal powder dose of the inhalable powder contained in the capsule is about 50%, 60%, or 70%, or 80%, or 90%. In one embodiment the FPF is about 50% to about 60% of the nominal powder dose of the inhalable powder contained in the inhaler. In one embodiment the FPF is about 55% to about 65% of the nominal powder dose of the inhalable powder contained in the inhaler.
In one embodiment the FPF is about 50% to about 70% of the nominal powder dose of the inhalable powder contained in the inhaler. In one embodiment the FPF is about 57%
to about 62% of the nominal powder dose of the inhalable powder contained in the inhaler. In one embodiment the FPF is about 50% to about 69% of the nominal powder dose of the inhalable powder contained in the inhaler. In one embodiment the FPF is about 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, or 65% of the nominal powder dose of the inhalable powder contained in the inhaler.
As used herein, the term "nominal powder dose" is the total amount of powder held in the capsule. As used herein, the term "nominal drug dose" is the total amount of drug (e.g. levodopa) contained in the nominal powder dose. The nominal powder dose is related to the nominal drug dose by the load percent of drug in the powder.
In one embodiment, the nominal powder dose is 25-50 mg by dry weight. In a further embodiment, the nominal powder dose is 25-40 mg by dry weight. In a still further embodiment, the nominal powder dose is 30-35 mg by dry weight or 32-38 mg by dry weight.
Another method for measuring the size distribution of airborne particles is the multi-stage liquid impinger (MSLI). The Multi-stage liquid Impinger (MSLI) operates on the same principles as the Anderson Cascade Impactor (ACT), but instead of eight stages there are five in the MSLI. Additionally, instead of each stage consisting of a solid plate, each MSLI stage consists of a methanol-wetted glass frit. The wetted stage is used to prevent bouncing and re-entrainment, which can occur using the ACT. The MSLI
is used to provide an indication of the flow rate dependence of the powder. This can be
- 5 -accomplished by operating the MSLI at 30, 60, and 90 L/min and measuring the fraction of the powder collected on stage 1 and the collection filter. If the fractions on each stage remain relatively constant across the different flow rates then the powder is considered to be approaching flow rate independence.
In one embodiment, the inhalable powders of the invention have a tap density of less than about 0.075 g/cm3. For example, the particles have a tap density between 0.02 g/cm3 and 0.075 g/cm3, between 0.02 g/cm3 and 0.05 g/cm3, between 0.03 g/cm3 and 0.06 g/cm3, between 0.03 g/cm3 and 0.04 g/cm3, or less than about 0.05 g/cm3, or a tap density less than about 0.04 g/cm3, a tap density less than about 0.03 g/cm3.
Tap density can be measured by using instruments known to those skilled in the art such as the Dual Platform Microprocessor Controlled Tap Density Tester (Vankel, N.C.) or a GEOPYC TM instrument (Micrometrics Instrument Corp., Norcross, GA, 30093). Tap density is a standard measure of the envelope mass density. Tap density can be determined using the method of USP Bulk Density and Tapped Density, United States Pharmacopia Convention, Rockville, Md., 10th Supplement, 4950-4951, 1999.
Features which can contribute to low tap density include irregular surface texture and porous structure. The envelope mass density of an isotropic particle is defined as the mass of the particle divided by the minimum sphere envelope volume within which it can be enclosed. In one embodiment of the invention, the particles have an envelope mass density of less than about 0.4 g/cm3.
The inhalable powder of the invention has a preferred particle size, e.g., a volume median geometric diameter (VMGD) of at least about 1 micron ( m). In one embodiment, the VMGD is greater than 5 m. In other embodiments, the VMGD is between about 5 m and 30 pm, between about 5 m and 10 pm, between about 7 m and 15 m and between about 7 m and 12 m. The diameter of the spray-dried particles, for example, the VMGD, can be measured using a laser diffraction instrument (for example Helos, manufactured by Sympatec, Princeton, N.J.). Other instruments for measuring particle diameter are well known in the art. The diameter of particles in a sample will range depending upon factors such as particle composition and methods of synthesis. The distribution of size of particles in a sample can be selected to permit optimal deposition to targeted sites within the respiratory tract.
In one embodiment, the inhalable powders of the invention have a tap density of less than about 0.075 g/cm3. For example, the particles have a tap density between 0.02 g/cm3 and 0.075 g/cm3, between 0.02 g/cm3 and 0.05 g/cm3, between 0.03 g/cm3 and 0.06 g/cm3, between 0.03 g/cm3 and 0.04 g/cm3, or less than about 0.05 g/cm3, or a tap density less than about 0.04 g/cm3, a tap density less than about 0.03 g/cm3.
Tap density can be measured by using instruments known to those skilled in the art such as the Dual Platform Microprocessor Controlled Tap Density Tester (Vankel, N.C.) or a GEOPYC TM instrument (Micrometrics Instrument Corp., Norcross, GA, 30093). Tap density is a standard measure of the envelope mass density. Tap density can be determined using the method of USP Bulk Density and Tapped Density, United States Pharmacopia Convention, Rockville, Md., 10th Supplement, 4950-4951, 1999.
Features which can contribute to low tap density include irregular surface texture and porous structure. The envelope mass density of an isotropic particle is defined as the mass of the particle divided by the minimum sphere envelope volume within which it can be enclosed. In one embodiment of the invention, the particles have an envelope mass density of less than about 0.4 g/cm3.
The inhalable powder of the invention has a preferred particle size, e.g., a volume median geometric diameter (VMGD) of at least about 1 micron ( m). In one embodiment, the VMGD is greater than 5 m. In other embodiments, the VMGD is between about 5 m and 30 pm, between about 5 m and 10 pm, between about 7 m and 15 m and between about 7 m and 12 m. The diameter of the spray-dried particles, for example, the VMGD, can be measured using a laser diffraction instrument (for example Helos, manufactured by Sympatec, Princeton, N.J.). Other instruments for measuring particle diameter are well known in the art. The diameter of particles in a sample will range depending upon factors such as particle composition and methods of synthesis. The distribution of size of particles in a sample can be selected to permit optimal deposition to targeted sites within the respiratory tract.
- 6 -
7 The particles of the inhalable powder of the invention preferably have a "mass median aerodynamic diameter" (MMAD), also referred to herein as "aerodynamic diameter", between about 1 iim and about 5 i.tm or any subrange encompassed between about 1 i.tm and about 5 i.tm. For example, the MMAD is between about 1 iim and about 3 rim, or the MMAD is between about 3 iim and about 5 iim. In one embodiment, the MMAD is between 1.5 lam and 2.5 lam. Experimentally, aerodynamic diameter can be determined by employing a gravitational settling method, whereby the time for an ensemble of powder particles to settle a certain distance is used to infer directly the aerodynamic diameter of the particles. An indirect method for measuring the mass median aerodynamic diameter (MMAD) is the multi-stage liquid impinger (MSLI).
The aerodynamic diameter, da,, can be calculated from the equation:
daer¨dg \IPtap where dg is the geometric diameter, for example the MMGD, and p is the powder density.
Powders for use in capsules of this invention are typically produced by spray drying. In some cases, spray-drying can produce extremely dry particles which may have poor handling properties and may be difficult to compact into a capsule in a dense manner. A nitrogen source with a specified moisture level may be flown over, across, or through the dry powder to add specific moisture content to the dry powder.
Such moisture can provide the desired working density of the powder. Spray drying methods in accordance with the invention are described in the Examples herein and in U.S. Patent Numbers: 6,848,197 and 8,197,845, incorporated herein by reference.
The inhalable powder comprising levodopa, for example, as described above is used to fill capsules suitable for use in an inhaler. The term "capsule material" as used herein refers to the material from which the shell of the capsule for inhalation is made. In one embodiment, the capsule material according to the invention is selected from among gelatin, cellulose derivatives, starch, starch derivatives, chitosan and synthetic plastics.
If gelatin is used as the capsule material, examples according to the invention may be selected from among polyethyleneglycol (PEG), PEG 3350, glycerol, sorbitol, propyleneglycol, PEO-PPO block copolymers and other polyalcohols and polyethers. If cellulose derivatives are used as the capsule material, examples according to the invention may be selected from hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose, methylcellulose, hydroxymethylcellulose and hydroxyethylcellulose. If synthetic plastics are used as the capsule material, examples according to the invention may be selected from polyethylene, polycarbonate, polyester, polypropylene and polyethylene terephthalate. In one embodiment, the capsule material further comprises titanium dioxide. In one preferred embodiment the capsule comprises HPMC and titanium dioxide. In one embodiment, the capsule comprises carrageenan.
In a further embodiment, the capsule comprises potassium chloride. In a still further embodiment, the capsule comprises, HPMC, carrageenan, potassium chloride, and titanium dioxide. In one embodiment, the capsule size is selected from 000, 00, 0, 1, or 2. In a specific embodiment, the capsule size is 00.
In one specific embodiment, the capsule is a hydroxypropylmethylcellulose (HPMC) capsule. In another specific embodiment, the capsule is a hydroxypropylmethylcellulose size 00 capsule. In one specific embodiment the capsule material comprises HPMC and titanium dioxide and the capsule size is 00.
In one embodiment, a 00 capsule contains between 15 and 50 grams of levodopa by dry weight. In another embodiment, a 00 capsule contains between 20 and 40 grams of levodopa by dry weight. In another embodiment, a 00 capsule contains between 25 and 35 grams of levodopa by dry weight. In another embodiment, a 00 capsule contains about 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 grams of levodopa by dry weight.
In one aspect of the invention, the powders have low electrostatic charge to enable high dispersion from the capsule.
The capsules of the invention are particularly suitable for use in a dry powder inhaler for the delivery of a dry powder composition comprising levodopa to a patient afflicted with, for example, Parkinson's disease and in need of treatment with levodopa.
The patient in need of treatment may require maintenance therapy for Parkinson's disease or rescue therapy for Parkinson's disease such as would be necessary in the case of an acute and/or freezing episode due to Parkinson's disease. In one embodiment, the capsules are used in a dry powder inhaler to deliver an effective amount of the dry powder composition to the patient in a single breath as is described in U.S.
Patent Numbers, 6,858,199 and 7,556,798 incorporated herein by reference.
The aerodynamic diameter, da,, can be calculated from the equation:
daer¨dg \IPtap where dg is the geometric diameter, for example the MMGD, and p is the powder density.
Powders for use in capsules of this invention are typically produced by spray drying. In some cases, spray-drying can produce extremely dry particles which may have poor handling properties and may be difficult to compact into a capsule in a dense manner. A nitrogen source with a specified moisture level may be flown over, across, or through the dry powder to add specific moisture content to the dry powder.
Such moisture can provide the desired working density of the powder. Spray drying methods in accordance with the invention are described in the Examples herein and in U.S. Patent Numbers: 6,848,197 and 8,197,845, incorporated herein by reference.
The inhalable powder comprising levodopa, for example, as described above is used to fill capsules suitable for use in an inhaler. The term "capsule material" as used herein refers to the material from which the shell of the capsule for inhalation is made. In one embodiment, the capsule material according to the invention is selected from among gelatin, cellulose derivatives, starch, starch derivatives, chitosan and synthetic plastics.
If gelatin is used as the capsule material, examples according to the invention may be selected from among polyethyleneglycol (PEG), PEG 3350, glycerol, sorbitol, propyleneglycol, PEO-PPO block copolymers and other polyalcohols and polyethers. If cellulose derivatives are used as the capsule material, examples according to the invention may be selected from hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose, methylcellulose, hydroxymethylcellulose and hydroxyethylcellulose. If synthetic plastics are used as the capsule material, examples according to the invention may be selected from polyethylene, polycarbonate, polyester, polypropylene and polyethylene terephthalate. In one embodiment, the capsule material further comprises titanium dioxide. In one preferred embodiment the capsule comprises HPMC and titanium dioxide. In one embodiment, the capsule comprises carrageenan.
In a further embodiment, the capsule comprises potassium chloride. In a still further embodiment, the capsule comprises, HPMC, carrageenan, potassium chloride, and titanium dioxide. In one embodiment, the capsule size is selected from 000, 00, 0, 1, or 2. In a specific embodiment, the capsule size is 00.
In one specific embodiment, the capsule is a hydroxypropylmethylcellulose (HPMC) capsule. In another specific embodiment, the capsule is a hydroxypropylmethylcellulose size 00 capsule. In one specific embodiment the capsule material comprises HPMC and titanium dioxide and the capsule size is 00.
In one embodiment, a 00 capsule contains between 15 and 50 grams of levodopa by dry weight. In another embodiment, a 00 capsule contains between 20 and 40 grams of levodopa by dry weight. In another embodiment, a 00 capsule contains between 25 and 35 grams of levodopa by dry weight. In another embodiment, a 00 capsule contains about 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 grams of levodopa by dry weight.
In one aspect of the invention, the powders have low electrostatic charge to enable high dispersion from the capsule.
The capsules of the invention are particularly suitable for use in a dry powder inhaler for the delivery of a dry powder composition comprising levodopa to a patient afflicted with, for example, Parkinson's disease and in need of treatment with levodopa.
The patient in need of treatment may require maintenance therapy for Parkinson's disease or rescue therapy for Parkinson's disease such as would be necessary in the case of an acute and/or freezing episode due to Parkinson's disease. In one embodiment, the capsules are used in a dry powder inhaler to deliver an effective amount of the dry powder composition to the patient in a single breath as is described in U.S.
Patent Numbers, 6,858,199 and 7,556,798 incorporated herein by reference.
- 8 -As used herein, the term "effective amount" means the amount needed to achieve the desired effect or efficacy. The actual effective amounts of drug can vary according to the specific drug or combination thereof being utilized, the particular composition formulated, the mode of administration, and the age, weight, condition of the patient, and severity of the episode being treated. In the case of a dopamine precursor, agonist or combination thereof it is an amount which reduces the Parkinson's symptoms which require therapy. Dosages for a particular patient are described herein and can be determined by one of ordinary skill in the art using conventional considerations, (e.g. by means of an appropriate, conventional pharmacological protocol). For example, effective amounts of oral levodopa range from about 50 milligrams (mg) to about 500 mg. In many instances, a common ongoing (oral) levodopa treatment schedule is mg eight (8) times a day.
The administration of more than one dopamine precursor, agonist or combination thereof, in particular levodopa, carbidopa, apomorphine, and other drugs can be provided, either simultaneously or sequentially in time. Carbidopa or benserazide, for example, is often administered to ensure that peripheral carboxylase activity is completely shut down. Intramuscular, subcutaneous, oral and other administration routes can be employed. In one embodiment, these other agents are delivered to the pulmonary system. These compounds or compositions can be administered before, after or at the same time. In a preferred embodiment, particles that are administered to the respiratory tract include both Levodopa and carbidopa. The term "co-administration" is used herein to mean that the specific dopamine precursor, agonist or combination thereof and/or other compositions are administered at times to treat the episodes, as well as the underlying conditions described herein.
In one embodiment chronic levodopa therapy includes the use of the pharmaceutical compositions described herein in a dry powder inhaler for pulmonary delivery of levodopa combined with oral carbidopa. In another embodiment, pulmonary delivery of levodopa is provided during the episode, while chronic treatment can employ conventional oral administration of levodopa/carbidopa. In a further embodiment chronic levodopa therapy includes the use of the pharmaceutical compositions described herein in a dry powder inhaler for pulmonary delivery of
The administration of more than one dopamine precursor, agonist or combination thereof, in particular levodopa, carbidopa, apomorphine, and other drugs can be provided, either simultaneously or sequentially in time. Carbidopa or benserazide, for example, is often administered to ensure that peripheral carboxylase activity is completely shut down. Intramuscular, subcutaneous, oral and other administration routes can be employed. In one embodiment, these other agents are delivered to the pulmonary system. These compounds or compositions can be administered before, after or at the same time. In a preferred embodiment, particles that are administered to the respiratory tract include both Levodopa and carbidopa. The term "co-administration" is used herein to mean that the specific dopamine precursor, agonist or combination thereof and/or other compositions are administered at times to treat the episodes, as well as the underlying conditions described herein.
In one embodiment chronic levodopa therapy includes the use of the pharmaceutical compositions described herein in a dry powder inhaler for pulmonary delivery of levodopa combined with oral carbidopa. In another embodiment, pulmonary delivery of levodopa is provided during the episode, while chronic treatment can employ conventional oral administration of levodopa/carbidopa. In a further embodiment chronic levodopa therapy includes the use of the pharmaceutical compositions described herein in a dry powder inhaler for pulmonary delivery of
- 9 -levodopa combined with oral benserazide. In another embodiment, pulmonary delivery of levodopa is provided during the episode, while chronic treatment can employ conventional oral administration of levodopa/ benserazide.
The present invention will be further understood by reference to the following non-limiting examples.
EXAMPLES
Example 1. Process one powder preparation Levodopa and DPPC at room temperature for 30 minutes, after which the required amounts of water and ethanol are weighed and transferred to the jacketed aqueous and non-jacketed organic phase feed vessels respectively. The jacket on the aqueous phase vessel is set to 55 C, and the weighed water is allowed to heat up to the 52.5 C, following which the required amount of sodium chloride and L-dopa are added to the aqueous phase vessel and the required amount of DPPC is added to the organic phase vessel, and all of them are allowed to dissolve by stirring. The aqueous feed vessel headspace is purged with nitrogen maintained at 70 scfh.
Spray drying is initiated by starting the drying gas flow (set to 95 kg/hr) and the exhaust, and the heater for the drying gas is set to 125 C. The product filter heater is turned on and set to 60 C, and the liquid skid heater is turned on and set to 55 C. After the spray dryer outlet temperature reaches 80 C, the atomizing gas (set to 22 g/min) and the blank solvents (aqueous flow = 28 mL/min and organic flow = 42 mL/min) are initiated and allowed to stabilize, and the system is allowed to cool and stabilize to an outlet temperature of 52.5 C. Product filter pulsing is initiated and product filter purge flow is set to 15 scfh. After the system stabilizes at 52.5 C, the liquid skid inlets are switched to feed solvents. Table 1 summarizes the parameters maintained during the entire operation.
The present invention will be further understood by reference to the following non-limiting examples.
EXAMPLES
Example 1. Process one powder preparation Levodopa and DPPC at room temperature for 30 minutes, after which the required amounts of water and ethanol are weighed and transferred to the jacketed aqueous and non-jacketed organic phase feed vessels respectively. The jacket on the aqueous phase vessel is set to 55 C, and the weighed water is allowed to heat up to the 52.5 C, following which the required amount of sodium chloride and L-dopa are added to the aqueous phase vessel and the required amount of DPPC is added to the organic phase vessel, and all of them are allowed to dissolve by stirring. The aqueous feed vessel headspace is purged with nitrogen maintained at 70 scfh.
Spray drying is initiated by starting the drying gas flow (set to 95 kg/hr) and the exhaust, and the heater for the drying gas is set to 125 C. The product filter heater is turned on and set to 60 C, and the liquid skid heater is turned on and set to 55 C. After the spray dryer outlet temperature reaches 80 C, the atomizing gas (set to 22 g/min) and the blank solvents (aqueous flow = 28 mL/min and organic flow = 42 mL/min) are initiated and allowed to stabilize, and the system is allowed to cool and stabilize to an outlet temperature of 52.5 C. Product filter pulsing is initiated and product filter purge flow is set to 15 scfh. After the system stabilizes at 52.5 C, the liquid skid inlets are switched to feed solvents. Table 1 summarizes the parameters maintained during the entire operation.
- 10 -Process Parameters (OC) Target value Inlet Temperature ( C) 125.0 Outlet Temperature ( C) 52.5 Drying Gas Rate (kg/hr) 95.0 Chamber Pressure ("we) -2.0 Atomization Gas Flow Rate (g/min) 22.0 Aqueous Flow (mL/min) 28.0 Organic flow (mL/min) 42.0 Product filter purge rate (scfh) 15.0 Table 1: Process parameters for spray drying Spray dried powder is collected every hour and transferred to a larger vessel under controlled conditions of 20 C and 15% RH. After the feed solvents run out, the liquid skid inlets are switched to blank and allowed to run for about 10 minutes, during which the final powder is collected and combined. After 10 minutes on blank solvent, system shutdown is initiated by turning off the liquid lines, atomization gas, drying gas heater, drying gas inlet and finally the exhaust.
This process results in a powder containing about 3.4% water by weight.
Example 2. Process two powder preparation with special drying Levodopa and DPPC at room temperature for 30 minutes, after which the required amounts of water and ethanol are weighed and transferred to the jacketed aqueous and non-jacketed organic phase feed vessels respectively. The jacket on the aqueous phase vessel is set to 55 C, and the weighed water is allowed to heat up to the 52.5 C, following which the required amount of sodium chloride and L-dopa are added to the aqueous phase vessel and the required amount of DPPC is added to the organic phase vessel, and all of them are allowed to dissolve by stirring. The aqueous feed vessel headspace is purged with nitrogen maintained at 70 scfh.
Spray drying is initiated by starting the drying gas flow (set to 95 kg/hr) and the exhaust, and the heater for the drying gas is set to 125 C. The product filter and the optimized purge gas heaters are turned on and set to 60 C, and the liquid skid heater is turned on and set to 55 C. After the spray dryer outlet temperature reaches 80 C, the atomizing gas (set to 22 g/min), the blank solvents (aqueous flow = 28 mL/min and
This process results in a powder containing about 3.4% water by weight.
Example 2. Process two powder preparation with special drying Levodopa and DPPC at room temperature for 30 minutes, after which the required amounts of water and ethanol are weighed and transferred to the jacketed aqueous and non-jacketed organic phase feed vessels respectively. The jacket on the aqueous phase vessel is set to 55 C, and the weighed water is allowed to heat up to the 52.5 C, following which the required amount of sodium chloride and L-dopa are added to the aqueous phase vessel and the required amount of DPPC is added to the organic phase vessel, and all of them are allowed to dissolve by stirring. The aqueous feed vessel headspace is purged with nitrogen maintained at 70 scfh.
Spray drying is initiated by starting the drying gas flow (set to 95 kg/hr) and the exhaust, and the heater for the drying gas is set to 125 C. The product filter and the optimized purge gas heaters are turned on and set to 60 C, and the liquid skid heater is turned on and set to 55 C. After the spray dryer outlet temperature reaches 80 C, the atomizing gas (set to 22 g/min), the blank solvents (aqueous flow = 28 mL/min and
- 11 -organic flow = 42 mL/min), and the optimized drying gas (set at 70 kg/hr) are initiated and allowed to stabilize, and the system is allowed to cool and stabilize to an outlet temperature of 52.5 C. Product filter pulsing is initiated and product filter purge flow is set to 15 scfh. After the system stabilizes at 52.5 C, the liquid skid inlets are switched to feed solvents. Table 2 summarizes the parameters maintained during the entire operation.
Process Parameters (OC) Target value Inlet Temperature ( C) 125.0 Outlet Temperature ( C) 52.5 Drying Gas Rate (kg/hr) 95.0 Chamber Pressure ("wc) -2.0 Atomization Gas Flow Rate (g/min) 22.0 Aqueous Flow (mL/min) 28.0 Organic flow (mL/min) 42.0 Optimized drying purge rate (kg/hr) 70.0 Optimized drying purge temperature ( C) 52.5 Product filter purge rate (scfh) 15.0 Table 2: Process parameters for spray drying Spray dried powder is collected every hour and transferred to a larger vessel under controlled conditions of 20 C and 15% RH. After the feed solvents run out, the liquid skid inlets are switched to blank and allowed to run for about 10 minutes, during which the final powder is collected and combined. After 10 minutes on blank solvent, system shutdown is initiated by turning off the liquid lines, optimized drying gas, atomization gas, drying gas heater, drying gas inlet and finally the exhaust.
This process results in a powder containing about 2.2% water by weight. This reduction in water content by 1% results in a significant improvement in product stability.
Sample 1: Based on bulk powder (pre-filling):
VMGD = 10.2 p.m; and Tap density = 0.033 g/cm3.
Process Parameters (OC) Target value Inlet Temperature ( C) 125.0 Outlet Temperature ( C) 52.5 Drying Gas Rate (kg/hr) 95.0 Chamber Pressure ("wc) -2.0 Atomization Gas Flow Rate (g/min) 22.0 Aqueous Flow (mL/min) 28.0 Organic flow (mL/min) 42.0 Optimized drying purge rate (kg/hr) 70.0 Optimized drying purge temperature ( C) 52.5 Product filter purge rate (scfh) 15.0 Table 2: Process parameters for spray drying Spray dried powder is collected every hour and transferred to a larger vessel under controlled conditions of 20 C and 15% RH. After the feed solvents run out, the liquid skid inlets are switched to blank and allowed to run for about 10 minutes, during which the final powder is collected and combined. After 10 minutes on blank solvent, system shutdown is initiated by turning off the liquid lines, optimized drying gas, atomization gas, drying gas heater, drying gas inlet and finally the exhaust.
This process results in a powder containing about 2.2% water by weight. This reduction in water content by 1% results in a significant improvement in product stability.
Sample 1: Based on bulk powder (pre-filling):
VMGD = 10.2 p.m; and Tap density = 0.033 g/cm3.
- 12 -Sample 2: Same but using VMGD measured on filled lot (60031):
VMGD = 8.6 pm; and Tap = 0.033 g/cm3.
Sample 1. Emitted powder from a dry powder inhaler with a resistance of 0.2 (28.3 LPM):
VMGD = 9.4 pm; and Tap density = 0.048 g/cm3.
Sample 2. Emitted powder from a dry powder inhaler with a resistance of 0.2 ( (60 LPM):
VMGD = 8.8 pm; and Tap density = 0.042 g/cm3.
The above particles are very low density for pulmonary products. These very low density particles are advantageous for packing into capsules. Because of the low density, these particles can be deaggregated or sheared prior to emission from an inhaler.
These deaggregated/sheared particles have good flow properties and expected deposition into the lungs.
While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims. It should also be understood that the embodiments described herein are not mutually exclusive and that features from the various embodiments may be combined in whole or in part in accordance with the invention.
VMGD = 8.6 pm; and Tap = 0.033 g/cm3.
Sample 1. Emitted powder from a dry powder inhaler with a resistance of 0.2 (28.3 LPM):
VMGD = 9.4 pm; and Tap density = 0.048 g/cm3.
Sample 2. Emitted powder from a dry powder inhaler with a resistance of 0.2 ( (60 LPM):
VMGD = 8.8 pm; and Tap density = 0.042 g/cm3.
The above particles are very low density for pulmonary products. These very low density particles are advantageous for packing into capsules. Because of the low density, these particles can be deaggregated or sheared prior to emission from an inhaler.
These deaggregated/sheared particles have good flow properties and expected deposition into the lungs.
While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims. It should also be understood that the embodiments described herein are not mutually exclusive and that features from the various embodiments may be combined in whole or in part in accordance with the invention.
- 13 -
Claims (41)
1. A pharmaceutical composition for pulmonary delivery comprising particles containing a pharmaceutical agent wherein the particles have a geometric size of greater than about 5 µm and a tap density of less than about 0.075 g/cm3.
2. The pharmaceutical composition of claim 1, wherein said tap density is from about 0.02 g/cm3 to 0.075 g/cm3.
3. The pharmaceutical composition of claim 1, wherein said tap density is from about 0.02 g/cm3 to 0.05 g/cm3.
4. The pharmaceutical composition of claim 1, wherein said tap density is from about 0.03 g/cm3 to 0.06 g/cm3.
5. The pharmaceutical composition of claim 1, wherein said tap density is from about 0.03 g/cm3 to 0.04 g/cm3.
6. The pharmaceutical composition of claim 1, wherein geometric size is about 5 µm to 30 µm.
7. The pharmaceutical composition of claim 1, wherein median geometric size is about 5 µm to 10 µm.
8. The pharmaceutical composition of claim 1, wherein median geometric size is about 7 µm to 15 µm.
9. The pharmaceutical composition of claim 1, wherein median geometric size is about 7 µm to 12 µm.
10. A method of delivering a pharmaceutical agent to the pulmonary system of a patient comprising the steps of:
providing a powder in a compartment and an inhaler to a patient wherein said powder comprises particles of a pharmaceutical agent;
dispersing the powder by breath actuation of the patient;
delivering the particles to the patient's respiratory system; and wherein upon dispersion of the powder, the particles delivered to the patient's respiratory system have a smaller median geometric diameter than the particles contained in said compartment.
providing a powder in a compartment and an inhaler to a patient wherein said powder comprises particles of a pharmaceutical agent;
dispersing the powder by breath actuation of the patient;
delivering the particles to the patient's respiratory system; and wherein upon dispersion of the powder, the particles delivered to the patient's respiratory system have a smaller median geometric diameter than the particles contained in said compartment.
11. The method of claim 10, wherein said powder has a tap density of less than about 0.75 g/cm3.
12. The method of claim 10, wherein said powder has a tap density is from about 0.02 g/cm3 to 0.075 g/cm3.
13. The method of claim 10, wherein said powder has a tap density is from about 0.025 g/cm3 to 0.055 g/cm3.
14. The method of claim 10, wherein said inhaler has a resistance of about 0.05 .sqroot.cm H2O/(L/min) to about 0.25 .sqroot.cm H2O/(L/min).
15. The method of claim 10, wherein said inhaler has a resistance of about 0.15 .sqroot.cm H2O/(L/min) to about 0.25 .sqroot.cm H2O/(L/min).
16. The method of claim 10, wherein said inhaler has a resistance of about 0.05 .sqroot.cm H2O/(L/min) to about 0.15 .sqroot.cm H2O/(L/min).
17. The method of claim 10, wherein said inhaler has a resistance of about 0.2 .sqroot.cm H2O/(L/min) to about 0.25 .sqroot.cm H2O/(L/min).
18. The method of claim 10, wherein said inhaler has a resistance of about 0.2 .sqroot.cm H2O/(L/min).
19. The method of claim 10, wherein the powder in said compartment has a median geometric diameter of greater than about 5 µm.
20. The method of claim 10, wherein the powder in said compartment has a median geometric diameter of about 5 µm to about 30 µm.
21. The method of claim 10, wherein the powder in said compartment has a median geometric diameter of about 5 µm to about 15 µm.
22. The method of claim 10, wherein the powder in said compartment has a median geometric diameter of about 7 µm to about 12 µm.
23. The method of claim 10, wherein the particles in said compartment have a median geometric diameter of 10-12 µm and the particles delivered to the patient's respiratory tract have a median geometric diameter of 8-9 µm.
24. The method of claim 10, wherein the particles delivered to the patient's respiratory tract have a 5% to 20% smaller median geometric diameter than the particles in said compartment.
25. The method of claim 10, wherein the particles delivered to the patient's respiratory tract have a 5% to 10% smaller median geometric diameter than the particles in said compartment.
26. The method of claim 10, wherein the particles delivered to the patient's respiratory tract have a 8% to 15% smaller median geometric diameter than the particles in said compartment.
27. A pharmaceutical composition for pulmonary delivery comprising particles of levodopa having a geometric size of greater than about 5 µm and a tap density of less than about 0.75 g/cm3.
28. The pharmaceutical composition of claims 1 or 27, wherein said particles comprise a phospholipid.
29. The pharmaceutical composition of claims 1 or 27, wherein said particles comprise a salt.
30. The pharmaceutical composition of claims 1 or 27, wherein said particles comprise a surfactant.
31. The pharmaceutical composition of claims 1 or 27, wherein said particles comprise a polymer.
32. The pharmaceutical composition of claims 1 or 27, wherein said particles comprise a sugar.
33. The pharmaceutical composition of claims 1 or 27, wherein said particles have an external surface area of greater than about 10 m2/g.
34. The pharmaceutical composition of claims 1 or 27, wherein said particles have an external surface area of greater than about 15 m2/g.
35. The pharmaceutical composition of claims 1 or 27, wherein said particles have an external surface area of greater than about 20 m2/g.
36. The pharmaceutical composition of claims 1 or 27, wherein said particles have an external surface area of about 10 m2/g to about 50 m2/g.
37. A pharmaceutical composition for pulmonary deliver comprising particles of levodopa having:
a geometric size of about 8 µm to about 12 µm; and a tap density of about 0.025 g/cm3 to about 0.050 g/cm3.
a geometric size of about 8 µm to about 12 µm; and a tap density of about 0.025 g/cm3 to about 0.050 g/cm3.
38. The pharmaceutical composition of claim 37, wherein said particles have an aerodynamic diameter of between about 2.5 µm and 5 µm.
39. The pharmaceutical composition of claim 37, wherein said particles have an external surface area of about 10 m2/g to about 50 m2/g.
40. The pharmaceutical composition of claim 37, wherein said particles further comprise a salt and a phospholipid.
41. A pharmaceutical composition for pulmonary delivery comprising particles of levodopa having:
a geometric size of about 8 µm to about 12 µm;
a tap density of about 0.025 g/cm3 to about 0.050 g/cm3;
a water content between 1.90 and 2.90 weight percent.
a geometric size of about 8 µm to about 12 µm;
a tap density of about 0.025 g/cm3 to about 0.050 g/cm3;
a water content between 1.90 and 2.90 weight percent.
Applications Claiming Priority (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261724781P | 2012-11-09 | 2012-11-09 | |
US61/724,781 | 2012-11-09 | ||
US13/679,245 US8545878B1 (en) | 2012-11-09 | 2012-11-16 | Capsules containing high doses of levodopa for pulmonary use |
US13/679,245 | 2012-11-16 | ||
US13/945,160 | 2013-07-18 | ||
US13/945,160 US8685442B1 (en) | 2012-11-09 | 2013-07-18 | Capsules containing high doses of levodopa for pulmonary use |
US201361884315P | 2013-09-30 | 2013-09-30 | |
US201361884319P | 2013-09-30 | 2013-09-30 | |
US201361884436P | 2013-09-30 | 2013-09-30 | |
US61/884,315 | 2013-09-30 | ||
US61/884,319 | 2013-09-30 | ||
US61/884,436 | 2013-09-30 | ||
PCT/US2013/069107 WO2014074797A1 (en) | 2012-11-09 | 2013-11-06 | Ultra low density pulmonary powders |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2890459A1 true CA2890459A1 (en) | 2014-05-15 |
CA2890459C CA2890459C (en) | 2022-08-23 |
Family
ID=50685169
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2890459A Active CA2890459C (en) | 2012-11-09 | 2013-11-08 | Ultra low density pulmonary powders |
CA2890454A Active CA2890454C (en) | 2012-11-09 | 2013-11-08 | Dosator for filling a capsule with powder |
CA2890451A Active CA2890451C (en) | 2012-11-09 | 2013-11-08 | High dose levodopa capsules for pulmonary use |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2890454A Active CA2890454C (en) | 2012-11-09 | 2013-11-08 | Dosator for filling a capsule with powder |
CA2890451A Active CA2890451C (en) | 2012-11-09 | 2013-11-08 | High dose levodopa capsules for pulmonary use |
Country Status (19)
Country | Link |
---|---|
US (3) | US9539211B2 (en) |
EP (5) | EP2916821B1 (en) |
JP (6) | JP6347786B2 (en) |
KR (6) | KR20220054703A (en) |
CN (4) | CN105120843A (en) |
AU (6) | AU2013342247C1 (en) |
BR (2) | BR112015010601B1 (en) |
CA (3) | CA2890459C (en) |
DK (1) | DK2916821T3 (en) |
ES (2) | ES2880271T3 (en) |
HK (5) | HK1212884A1 (en) |
MX (3) | MX2015005767A (en) |
NZ (4) | NZ747376A (en) |
PL (1) | PL2916821T3 (en) |
PT (1) | PT2916821T (en) |
RU (2) | RU2670987C2 (en) |
SG (5) | SG11201503543PA (en) |
WO (3) | WO2014074797A1 (en) |
ZA (2) | ZA201504060B (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112015010601B1 (en) * | 2012-11-09 | 2022-07-19 | Civitas Therapeutics, Inc. | PHARMACEUTICAL COMPOSITION AND USE OF THE COMPOSITION |
MA40910A (en) * | 2014-11-07 | 2017-09-12 | Civitas Therapeutics Inc | RAPAMYCIN POWDERS FOR PULMONARY ADMINISTRATION |
KR101748796B1 (en) * | 2015-09-30 | 2017-06-19 | 한미약품 주식회사 | Inhalation capsule with enhanced delivery rate of active ingredients |
WO2017133749A1 (en) * | 2016-02-06 | 2017-08-10 | Harro Höfliger Verpackungsmaschinen GmbH | Pipette |
ITUA20163077A1 (en) * | 2016-05-02 | 2017-11-02 | Mg 2 Srl | POWER SUPPLY GROUP FOR DETERMINATION OF GRANULES, IN PARTICULAR MICROGRANULES, IN CAPSULES |
GB2550961A (en) * | 2016-06-03 | 2017-12-06 | Res Center Pharmaceutical Engineering Gmbh | Apparatus for dosing a solid material into at least one receptacle |
CN106394953A (en) * | 2016-06-24 | 2017-02-15 | 湖南千山制药机械股份有限公司 | Vacuum filling system |
WO2019060797A1 (en) | 2017-09-22 | 2019-03-28 | Teva Branded Pharmaceutical Products R&D, Inc. | Method for manufacture of inhalation powders |
WO2019067708A1 (en) | 2017-09-27 | 2019-04-04 | Teva Branded Pharmaceutical Products R&D, Inc. | Method for particle size reduction |
PT3833964T (en) | 2018-08-07 | 2023-08-17 | Norton Waterford Ltd | Application of raman spectroscopy for the manufacture of inhalation powders |
EP3608015B1 (en) * | 2018-08-08 | 2021-10-06 | Harro Höfliger Verpackungsmaschinen GmbH | Powder provision device for a powder metering apparatus |
CN108995838A (en) * | 2018-09-10 | 2018-12-14 | 江西克莱威纳米碳材料有限公司 | A kind of powder tinning system |
CN109178367B (en) * | 2018-10-15 | 2021-01-26 | 楚天科技股份有限公司 | Filling head and filling device for powder split charging |
CN110040519A (en) * | 2019-04-30 | 2019-07-23 | 裕东(中山)机械工程有限公司 | A kind of quantitatively Dual-Phrase Distribution of Gas olid conveying device and dose delivery system |
RU2716294C1 (en) * | 2019-10-04 | 2020-03-11 | Владимир Александрович Трусов | Tandem reflecting furnace for aluminum scrap remelting |
IT202000008962A1 (en) * | 2020-04-24 | 2021-10-24 | Romaco Srl | EQUIPMENT FOR FILLING CONTAINERS WITH A POWDER MATERIAL |
CN116546980A (en) * | 2020-12-11 | 2023-08-04 | 江苏恒瑞医药股份有限公司 | Pharmaceutical composition for pulmonary delivery |
Family Cites Families (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2540059A (en) * | 1947-08-02 | 1951-01-30 | American Cyanamid Co | Method of and apparatus for measuring and filling powders volumetrically |
US3656518A (en) * | 1967-03-27 | 1972-04-18 | Perry Ind Inc | Method and apparatus for measuring and dispensing predetermined equal amounts of powdered material |
US3847191A (en) * | 1971-08-23 | 1974-11-12 | T Aronson | Means and methods for measuring and dispensing equal amounts of powdered material |
IT1069354B (en) * | 1976-03-05 | 1985-03-25 | Zanasi Nigris Spa | IMPROVEMENTS IN VOLUME DOSING UNITS |
IT1156553B (en) * | 1982-03-03 | 1987-02-04 | Mg 2 Spa | PROCEDURE FOR WITHDRAWING A PREFIXED QUANTITY OF POWDER FROM INSIDE A ROTATING CONTAINER AND FOR STORING SUCH QUANTITY INSIDE A BOTTOM OF A CONTAINER OF SHAPE OF ANY AND MACHINE WHICH OPERATES THAT PROCEDURE |
JPS59115201A (en) * | 1982-12-10 | 1984-07-03 | 武田薬品工業株式会社 | Treating machine for powdered and granular body |
IT1245757B (en) * | 1991-01-15 | 1994-10-14 | Mg 2 Spa | MACHINE FOR DOSING PHARMACEUTICAL PRODUCTS IN POWDER. |
US5111642A (en) * | 1991-01-23 | 1992-05-12 | Macofar S.P.A. | Machine for the dosage of powders in capsules, in particular for the pharmaceutical industry |
US5756123A (en) | 1994-12-01 | 1998-05-26 | Japan Elanco Co., Ltd. | Capsule shell |
US5826633A (en) * | 1996-04-26 | 1998-10-27 | Inhale Therapeutic Systems | Powder filling systems, apparatus and methods |
ATE247948T1 (en) * | 1996-04-29 | 2003-09-15 | Dura Pharma Inc | METHOD FOR INHALING DRY POWDER |
US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
US20020052310A1 (en) | 1997-09-15 | 2002-05-02 | Massachusetts Institute Of Technology The Penn State Research Foundation | Particles for inhalation having sustained release properties |
US6652837B1 (en) * | 1996-05-24 | 2003-11-25 | Massachusetts Institute Of Technology | Preparation of novel particles for inhalation |
US6503480B1 (en) | 1997-05-23 | 2003-01-07 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US6254854B1 (en) | 1996-05-24 | 2001-07-03 | The Penn Research Foundation | Porous particles for deep lung delivery |
US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
USRE37053E1 (en) | 1996-05-24 | 2001-02-13 | Massachusetts Institute Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
EP0971698A4 (en) * | 1996-12-31 | 2006-07-26 | Nektar Therapeutics | Aerosolized hydrophobic drug |
US7052678B2 (en) | 1997-09-15 | 2006-05-30 | Massachusetts Institute Of Technology | Particles for inhalation having sustained release properties |
US20030077227A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
US20040028735A1 (en) | 1997-11-14 | 2004-02-12 | Unchalee Kositprapa | Pharmaceutical formulation |
ATE270097T1 (en) * | 1998-04-09 | 2004-07-15 | Celanese Ventures Gmbh | PARTICULAR ACTIVE CARRIER FOR PULMONARY APPLICATION |
MA25590A1 (en) * | 1998-09-14 | 2002-12-31 | Inhale Therapeutic Syst | ACTIVE AGENT FOR DRY POWDER DELIVERY |
IT1304779B1 (en) * | 1998-12-03 | 2001-03-29 | Ima Spa | DISC AND PESTEL DISPENSER, INTERMITTENTLY OPERATING, SINGLE-SIDED, PARTICULARLY SUITABLE FOR PACKAGING DOSES |
US6858199B1 (en) | 2000-06-09 | 2005-02-22 | Advanced Inhalation Research, Inc. | High efficient delivery of a large therapeutic mass aerosol |
US6586008B1 (en) | 1999-08-25 | 2003-07-01 | Advanced Inhalation Research, Inc. | Use of simple amino acids to form porous particles during spray drying |
US7252840B1 (en) | 1999-08-25 | 2007-08-07 | Advanced Inhalation Research, Inc. | Use of simple amino acids to form porous particles |
GB9926335D0 (en) * | 1999-11-05 | 2000-01-12 | Powderject Res Ltd | Apparatus and method for dispensing small quantities of particles |
GB2356386A (en) | 1999-11-17 | 2001-05-23 | Tagra Biotechnologies Ltd | Microencapsulation |
US20030180352A1 (en) | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
GB0014082D0 (en) * | 2000-06-10 | 2000-08-02 | Glaxo Group Ltd | Method and apparatus for transferring a defined quantity of powder |
US6514482B1 (en) | 2000-09-19 | 2003-02-04 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
US6613308B2 (en) | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
US20020122773A1 (en) * | 2000-12-20 | 2002-09-05 | Michel Pairet | Pharmaceutical compositions based on anticholinergics and dopamine agonists |
CA2433335C (en) | 2000-12-29 | 2010-04-20 | Advanced Inhalation Research, Inc. | Particles for inhalation having sustained release properties |
US6766799B2 (en) | 2001-04-16 | 2004-07-27 | Advanced Inhalation Research, Inc. | Inhalation device |
US6848197B2 (en) | 2001-04-18 | 2005-02-01 | Advanced Inhalation Research, Inc. | Control of process humidity to produce large, porous particles |
DE60223017T2 (en) * | 2001-04-20 | 2008-07-31 | Glaxo Group Ltd., Greenford | MEASURING METHOD FOR PARTICLE MATERIAL |
CA2445650A1 (en) | 2001-05-25 | 2002-12-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Combination of a dopamine d2-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways |
US6531153B2 (en) | 2001-05-29 | 2003-03-11 | Drugtech Corporation | Composition with sustained release of levodopa and carbidopa |
US7122143B2 (en) * | 2001-09-28 | 2006-10-17 | Mcneil-Ppc, Inc. | Methods for manufacturing dosage forms |
US6767200B2 (en) * | 2001-09-28 | 2004-07-27 | Mcneil-Ppc, Inc. | Systems, methods and apparatuses for manufacturing dosage forms |
DK1455755T3 (en) * | 2001-11-20 | 2013-07-15 | Civitas Therapeutics Inc | Improved particle composition for delivery in lung |
US7754242B2 (en) | 2002-03-20 | 2010-07-13 | Alkermes, Inc. | Inhalable sustained therapeutic formulations |
WO2003079885A2 (en) | 2002-03-20 | 2003-10-02 | Advanced Inhalation Research, Inc. | Inhalable sustained therapeutic formulations |
US7008644B2 (en) | 2002-03-20 | 2006-03-07 | Advanced Inhalation Research, Inc. | Method and apparatus for producing dry particles |
PT1485154E (en) | 2002-03-20 | 2008-06-17 | Alkermes Inc | Powder inhalation device |
US20110123574A1 (en) * | 2002-03-20 | 2011-05-26 | Alkermes, Inc. | Inhalable sustained therapeutic formulations |
ES2389156T3 (en) * | 2002-03-20 | 2012-10-23 | Civitas Therapeutics, Inc. | Lung administration of levodopa |
CA2483687A1 (en) * | 2002-05-13 | 2003-11-20 | Alexza Molecular Delivery Corporation | Delivery of drug amines through an inhalation route |
US20040060265A1 (en) * | 2002-06-27 | 2004-04-01 | Nektar Therapeutics | Controlling the flow of a powder |
US6941980B2 (en) * | 2002-06-27 | 2005-09-13 | Nektar Therapeutics | Apparatus and method for filling a receptacle with powder |
LT1531794T (en) | 2002-06-28 | 2017-08-25 | Civitas Therapeutics, Inc. | Inhalable epinephrine |
ITBO20020525A1 (en) * | 2002-08-08 | 2004-02-09 | Ima Spa | OPERATING MACHINE. |
WO2004047974A1 (en) * | 2002-11-26 | 2004-06-10 | Universiteit Gent | Process and apparatus for continuous wet granulation of power material |
DE10255387A1 (en) * | 2002-11-28 | 2004-06-09 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New tiotropium-containing powder formulation for inhalation |
US7763280B2 (en) | 2002-11-28 | 2010-07-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tiotropium containing powder formulation for inhalation |
AU2004231342A1 (en) * | 2003-04-14 | 2004-11-04 | Vectura Ltd | Dry power inhaler devices and dry power formulations for enhancing dosing efficiency |
DE20309279U1 (en) * | 2003-06-12 | 2004-10-21 | Harro Höfliger Verpackungsmaschinen GmbH | Filter piston unit for filling predetermined volumes of powdery materials into containers comprises a hollow cylindrical piston with a transverse slit and an opposing internal groove in its wall |
US7134459B2 (en) * | 2003-06-12 | 2006-11-14 | Symyx Technologies, Inc. | Methods and apparatus for mixing powdered samples |
EP1635762B1 (en) | 2003-06-13 | 2021-03-03 | Civitas Therapeutics, Inc. | Low dose pharmaceutical powders for inhalation |
SE0303269L (en) * | 2003-12-03 | 2005-06-04 | Microdrug Ag | Medical product |
KR20070007075A (en) * | 2003-12-31 | 2007-01-12 | 사이덱스 인크 | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
SE0401842D0 (en) * | 2004-07-12 | 2004-07-12 | Dizlin Medical Design Ab | Infusion and injection solution of levodopa |
GB0425758D0 (en) * | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
US20060216345A1 (en) | 2005-03-24 | 2006-09-28 | Sun Pharmaceutical Industries Limited | Oral pharmaceutical composition including paroxetine |
US20060222699A1 (en) | 2005-03-29 | 2006-10-05 | Jonathan Gilinski | Flavored vegetarian cellulose capsule and methods for producing said capsule. |
EP1917301B1 (en) * | 2005-08-05 | 2014-04-23 | 3M Innovative Properties Company | Compositions exhibiting improved flowability |
AR055106A1 (en) | 2005-08-05 | 2007-08-08 | Osmotica Pharmaceutical Argent | SOLID PHARMACEUTICAL COMPOSITION OF EXTENDED LIBERATION CONTAINING CARBIDOPA AND LEVODOPA |
DE102005039765A1 (en) * | 2005-08-23 | 2007-03-01 | Robert Bosch Gmbh | sensing device |
GB0523576D0 (en) * | 2005-11-18 | 2005-12-28 | Theradeas Ltd | Drug composition and its use in therapy |
WO2007092088A1 (en) * | 2005-12-28 | 2007-08-16 | Nektar Therapeutics | Compositions comprising amphotericin b |
DE602005020334D1 (en) * | 2005-12-29 | 2010-05-12 | Mg2 Srl | Device for filling capsules with a product |
CN101453993A (en) * | 2006-04-03 | 2009-06-10 | 伊萨·奥迪迪 | Controlled release delivery device comprising an organosol coat |
US20080063722A1 (en) | 2006-09-08 | 2008-03-13 | Advanced Inhalation Research, Inc. | Composition of a Spray-Dried Powder for Pulmonary Delivery of a Long Acting Neuraminidase Inhibitor (LANI) |
US20080066739A1 (en) | 2006-09-20 | 2008-03-20 | Lemahieu Edward | Methods and systems of delivering medication via inhalation |
ES2895666T3 (en) | 2006-10-27 | 2022-02-22 | Capsugel Belgium Nv | Hydroxypropylmethylcellulose hard capsules and manufacturing process |
AU2007338631A1 (en) | 2006-12-22 | 2008-07-03 | Combinatorx, Incorporated | Pharmaceutical compositions for treatment of parkinson's disease and related disorders |
AU2008258596B2 (en) | 2007-06-04 | 2013-02-14 | Egalet Ltd | Controlled release pharmaceutical compositions for prolonged effect |
WO2008156586A2 (en) | 2007-06-12 | 2008-12-24 | Alkermes, Inc. | Inhalation device for powdered substances |
PE20090907A1 (en) * | 2007-07-21 | 2009-08-05 | Boehringer Ingelheim Int | NEW POWDER DRUGS CONTAINING THOTROPE AND SALMETEROL, AS WELL AS LACTOSE AS AN EXCIPIENT |
WO2009026434A1 (en) | 2007-08-21 | 2009-02-26 | Alkermes, Inc. | Pulmonary pharmaceutical formulations |
GB2454480A (en) | 2007-11-07 | 2009-05-13 | Vectura Group Plc | Pulmonary inhalation of levodopa containing compositions in the treatment of Parkinsons disease and other central nervous system disorders |
AU2009257311B2 (en) * | 2008-06-13 | 2014-12-04 | Mannkind Corporation | A dry powder inhaler and system for drug delivery |
US20100074947A1 (en) | 2008-06-13 | 2010-03-25 | Adrian Brown | Pharmaceutical Formulations |
US8485180B2 (en) * | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
WO2010035273A2 (en) | 2008-09-29 | 2010-04-01 | Intec Pharma Ltd. | Novel gastroretentive delivery system |
IT1390803B1 (en) * | 2008-09-30 | 2011-10-19 | Mg2 Srl | EQUIPMENT FOR DOSING PULVERULATING OR GRANULAR MATERIALS IN CAPSULES OR SIMILAR |
US8399513B2 (en) | 2008-10-20 | 2013-03-19 | Xenoport, Inc. | Levodopa prodrug mesylate hydrate |
CA2744655A1 (en) * | 2008-11-27 | 2010-06-03 | Boehringer Ingelheim International Gmbh | Novel powdered crystalline medicines for inhalation |
RU2577698C2 (en) * | 2009-03-26 | 2016-03-20 | Пулмэтрикс, Инк. | Dry powder formulations and methods of treating pulmonary diseases |
SG10201401712QA (en) * | 2009-04-24 | 2014-08-28 | Iceutica Pty Ltd | Method for the production of commercial nanoparticle and microparticle powders |
IT1394027B1 (en) * | 2009-05-11 | 2012-05-25 | Mg 2 Srl | MACHINE FOR FILLING CAPSULES WITH PHARMACEUTICALS |
US8359815B2 (en) * | 2009-05-11 | 2013-01-29 | Mg 2—S.R.L. | Machine for filling capsules with pharmaceutical products |
GB0918450D0 (en) * | 2009-10-21 | 2009-12-09 | Innovata Ltd | Composition |
RU2445119C2 (en) * | 2010-05-25 | 2012-03-20 | Сергей Викторович Чепур | Pharmaceutical composition and method for pulmonary administration thereof |
US20120164233A1 (en) | 2010-07-30 | 2012-06-28 | Ranbaxy Laboratories Limited | Pulsatile release pharmaceutical formulation of dexlansoprazole |
WO2012030664A1 (en) * | 2010-08-30 | 2012-03-08 | Pulmatrix, Inc. | Dry powder formulations and methods for treating pulmonary diseases |
TW201304822A (en) * | 2010-11-15 | 2013-02-01 | Vectura Ltd | Compositions and uses |
WO2014066206A1 (en) | 2012-10-22 | 2014-05-01 | Civitas Therapeutics , Inc. | Reducing inter-patient variability of levodopa plasma concentrations |
EP2908805B1 (en) | 2012-10-22 | 2021-06-09 | Civitas Therapeutics, Inc. | Levodopa formulations for rapid relief of parkinson's disease |
BR112015010601B1 (en) | 2012-11-09 | 2022-07-19 | Civitas Therapeutics, Inc. | PHARMACEUTICAL COMPOSITION AND USE OF THE COMPOSITION |
US8545878B1 (en) | 2012-11-09 | 2013-10-01 | Civitas Therapeutics, Inc. | Capsules containing high doses of levodopa for pulmonary use |
EP3831375A1 (en) | 2014-04-21 | 2021-06-09 | Civitas Therapeutics, Inc. | Rapid relief of motor fluctuations in parkinson's disease |
-
2013
- 2013-11-06 BR BR112015010601-3A patent/BR112015010601B1/en active IP Right Grant
- 2013-11-06 WO PCT/US2013/069107 patent/WO2014074797A1/en active Application Filing
- 2013-11-08 KR KR1020227013071A patent/KR20220054703A/en active Application Filing
- 2013-11-08 NZ NZ747376A patent/NZ747376A/en unknown
- 2013-11-08 MX MX2015005767A patent/MX2015005767A/en active IP Right Grant
- 2013-11-08 ES ES13852608T patent/ES2880271T3/en active Active
- 2013-11-08 WO PCT/US2013/069102 patent/WO2014074795A1/en active Application Filing
- 2013-11-08 NZ NZ73345913A patent/NZ733459A/en active IP Right Revival
- 2013-11-08 SG SG11201503543PA patent/SG11201503543PA/en unknown
- 2013-11-08 JP JP2015541915A patent/JP6347786B2/en active Active
- 2013-11-08 CA CA2890459A patent/CA2890459C/en active Active
- 2013-11-08 RU RU2015121091A patent/RU2670987C2/en active
- 2013-11-08 EP EP13852876.5A patent/EP2916821B1/en active Active
- 2013-11-08 BR BR112015010603-0A patent/BR112015010603B1/en active IP Right Grant
- 2013-11-08 JP JP2015541917A patent/JP6348501B2/en active Active
- 2013-11-08 KR KR1020157015346A patent/KR102337781B1/en active IP Right Grant
- 2013-11-08 JP JP2015541916A patent/JP6836834B2/en active Active
- 2013-11-08 NZ NZ708682A patent/NZ708682A/en unknown
- 2013-11-08 KR KR1020237025814A patent/KR20230116102A/en not_active Application Discontinuation
- 2013-11-08 SG SG11201503547TA patent/SG11201503547TA/en unknown
- 2013-11-08 PL PL13852876T patent/PL2916821T3/en unknown
- 2013-11-08 CN CN201380069936.3A patent/CN105120843A/en active Pending
- 2013-11-08 SG SG10201706465XA patent/SG10201706465XA/en unknown
- 2013-11-08 KR KR1020157015345A patent/KR102257164B1/en active IP Right Grant
- 2013-11-08 MX MX2015005768A patent/MX371008B/en active IP Right Grant
- 2013-11-08 CA CA2890454A patent/CA2890454C/en active Active
- 2013-11-08 ES ES13852876T patent/ES2844153T3/en active Active
- 2013-11-08 AU AU2013342247A patent/AU2013342247C1/en active Active
- 2013-11-08 DK DK13852876.5T patent/DK2916821T3/en active
- 2013-11-08 CN CN201380068998.2A patent/CN104918607B/en active Active
- 2013-11-08 KR KR1020217039998A patent/KR20210152020A/en not_active Application Discontinuation
- 2013-11-08 RU RU2015121092A patent/RU2676093C2/en active
- 2013-11-08 AU AU2013342248A patent/AU2013342248B2/en active Active
- 2013-11-08 PT PT138528765T patent/PT2916821T/en unknown
- 2013-11-08 EP EP13853467.2A patent/EP2925611B1/en active Active
- 2013-11-08 SG SG10201707103SA patent/SG10201707103SA/en unknown
- 2013-11-08 EP EP20202500.3A patent/EP3815679A1/en active Pending
- 2013-11-08 SG SG10202109328Q patent/SG10202109328QA/en unknown
- 2013-11-08 CN CN201811101094.6A patent/CN109106697B/en active Active
- 2013-11-08 WO PCT/US2013/069104 patent/WO2014074796A1/en active Application Filing
- 2013-11-08 CA CA2890451A patent/CA2890451C/en active Active
- 2013-11-08 AU AU2013342246A patent/AU2013342246B2/en active Active
- 2013-11-08 KR KR1020217015347A patent/KR102389785B1/en active IP Right Grant
- 2013-11-08 EP EP13852608.2A patent/EP2916826B1/en active Active
- 2013-11-08 NZ NZ70868413A patent/NZ708684A/en unknown
- 2013-11-08 EP EP21170515.7A patent/EP3957301A1/en active Pending
- 2013-11-08 CN CN201911132605.5A patent/CN110833539A/en active Pending
-
2015
- 2015-05-07 MX MX2020012506A patent/MX2020012506A/en unknown
- 2015-05-08 US US14/707,071 patent/US9539211B2/en active Active
- 2015-05-08 US US14/707,053 patent/US9642812B2/en active Active
- 2015-06-05 ZA ZA2015/04060A patent/ZA201504060B/en unknown
- 2015-06-05 ZA ZA2015/04058A patent/ZA201504058B/en unknown
-
2016
- 2016-01-22 HK HK16100777.1A patent/HK1212884A1/en unknown
- 2016-02-02 HK HK16101181.9A patent/HK1213186A1/en unknown
- 2016-02-02 HK HK16101182.8A patent/HK1213187A1/en unknown
- 2016-02-16 HK HK16101648.6A patent/HK1213535A1/en unknown
- 2016-03-15 HK HK16102954.2A patent/HK1214957A1/en unknown
-
2017
- 2017-03-31 US US15/475,624 patent/US10238607B2/en active Active
- 2017-12-19 AU AU2017279626A patent/AU2017279626B2/en active Active
-
2018
- 2018-05-29 JP JP2018102474A patent/JP6721629B2/en active Active
- 2018-05-31 JP JP2018104193A patent/JP6669808B2/en active Active
- 2018-06-27 AU AU2018204674A patent/AU2018204674B2/en active Active
- 2018-08-30 AU AU2018222983A patent/AU2018222983B2/en active Active
-
2019
- 2019-07-11 JP JP2019129175A patent/JP2019213867A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018222983B2 (en) | Ultra Low Density Pulmonary Powders | |
AU2020250195B2 (en) | Rapamycin Powders for Pulmonary Delivery | |
JP2024009112A (en) | Surfactant formulations for inhalation | |
JP2023144081A (en) | Surfactant formulations for inhalation | |
KR20170068497A (en) | Formulations containing tiotropium, amino acid and acid and methods thereof | |
WO2022187222A1 (en) | Dihydroergotamine dry power formulations and methods of use | |
EP3316865A1 (en) | Triptan powders for pulmonary delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20181015 |
|
EEER | Examination request |
Effective date: 20181015 |